Browse News
Filter News
Found 607 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
Biologics Market Size to Hit Around USD 1. 37 Trillion By 2033
4/17/2024
According to the latest Research by Nova One Advisor, the global biologics market size was exhibited at USD 511.04 billion in 2024 and is projected to hit around USD 1,374.51 billion by 2033, growing at a CAGR of 10.4% during the forecast period 2024 to 2033.
-
Active Pharmaceutical Ingredients Market Size to Increase USD 416.15 Billion By 2033
4/15/2024
The global active pharmaceutical ingredients market size was evaluated at USD 237.48 billion in 2023 and it is expected to increase around USD 416.15 billion by 2033 with a CAGR of 5.77% from 2024 to 2033.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
4/11/2024
Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2024 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 25, 2024.
-
Bristol Myers Squibb-backed TORL BioTherapeutics announced Wednesday it will use proceeds from the Series B-2 financing round to advance its pipeline of antibody-drug conjugate therapies.
-
Xencor Appoints Bart Cornelissen as Chief Financial Officer
4/9/2024
Xencor, Inc. today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer.
-
As the antibody-drug conjugate space continues to heat up, Merck has acquired preclinical startup Abceutics—spun out of the University at Buffalo—and its novel platform that aims to make ADC therapeutics safer.
-
2024 began with several biopharma players posting positive Phase III data that could mean new market share for the companies and longer survival times and quality of life for patients.
-
Tempus Releases New Data at AACR Showcasing Ways to Analyze Multimodal Data to Highlight Potential Therapeutic Routes for HER2-Directed Antibody-Drug Conjugates in Several Tumor Types
4/8/2024
Tempus, a leader in artificial intelligence and precision medicine, will present new data along with Pfizer at the AACR 2024 Annual Meeting.
-
Alongside the abrupt departure of Chinese biotech WuXi from BIO, Congress is rattling sabers over perceived national security implications of the U.S.’s R&D relationship with the country.
-
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
3/27/2024
Pieris Pharmaceuticals, Inc. provided a corporate update announcing a strategy to maximize its ability to capture the potential milestones from its 4-1BB bispecific Mabcalin® protein immuno-oncology assets partnered with Pfizer, Boston Pharmaceuticals, and Servier.
-
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
3/20/2024
LAVA Therapeutics N.V. today announced recent corporate highlights and financial results for the fourth quarter and year ended December 31, 2023.
-
Faron’s Financial Statement Release January 1 to December 31, 2023
3/13/2024
Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on tackling cancers via novel myeloid cell targeted immunotherapies, announced audited full-year financial results for January 1 to December 31, 2023 and provided an overview of recent corporate developments.
-
Antibody-drug conjugate Adcetris, when used with rituximab or lenalidomide, improved overall survival in patients with relapsed or refractory diffuse large B-cell lymphoma. Pfizer secured access to Seagen’s ADC in March 2023.
-
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
3/12/2024
Pfizer Inc. announced that a Phase 3 study of the antibody-drug conjugate ADCETRIS® in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma showed a statistically significant and clinically meaningful improvement in overall survival compared to lenalidomide and rituximab plus placebo.
-
RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024
3/11/2024
RemeGen Co. Ltd. recently gave an oral presentation on an interim analysis of the evaluation of the Company's proprietary Disitamab Vedotin, an investigational anti-HER2 antibody-drug conjugate targeting prevalent solid tumor cancers with significant unmet medical needs, at the European Congress on Gynaecological Oncology held in Barcelona from March 7-10, 2024.
-
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023
3/5/2024
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced that Pfizer has achieved a clinical development milestone for PF-08046052, prompting the first milestone payment of $7 Million to LAVA.
-
MBrace Therapeutics Appoints Steve Alley as Chief Scientific Officer
3/5/2024
MBrace™ Therapeutics, Inc. today announced the appointment of Steve Alley, Ph.D., as chief scientific officer.